Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Depreciation & Amortization (CF) (2016 - 2025)

Regenxbio has reported Depreciation & Amortization (CF) over the past 11 years, most recently at $3.9 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $3.9 million for Q4 2025, down 3.83% from a year ago — trailing twelve months through Dec 2025 was $15.6 million (down 3.7% YoY), and the annual figure for FY2025 was $15.6 million, down 3.7%.
  • Depreciation & Amortization (CF) for Q4 2025 was $3.9 million at Regenxbio, roughly flat from $3.9 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for RGNX hit a ceiling of $4.4 million in Q2 2023 and a floor of $1.9 million in Q1 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $3.9 million (2025), compared with a mean of $3.6 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 67.8% in 2023 and later fell 9.4% in 2024.
  • Regenxbio's Depreciation & Amortization (CF) stood at $2.6 million in 2021, then skyrocketed by 55.83% to $4.1 million in 2022, then rose by 4.81% to $4.3 million in 2023, then fell by 6.77% to $4.0 million in 2024, then fell by 3.83% to $3.9 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $3.9 million (Q4 2025), $3.9 million (Q3 2025), and $3.9 million (Q2 2025) per Business Quant data.